Check-Cap recently announced that it has received approval from the Israeli Ministry of Health Medical Device division (AMAR) to start marketing its C-Scan System.
The C-Scan System is an ingestible capsules used for preparation-free colorectal cancer screening. The system received CE Mark approve in January this year.
“We are excited to receive approval from the Israeli Ministry of Health to initiate commercial sales in Israel of our C-Scan system. We believe that this approval reinforces the potential of the C-Scan system to increase CRC screening adherence and precancerous detection to ultimately reduce mortality by offering a preparation free, non-invasive and patient-friendly CRC screening option,” Alex Ovadia, CEO of Check-Cap, said in a press release. “We look forward to achieving our near-term planned milestones, which include commercializing the C-Scan system in Israel in the second quarter of 2019, pending extension of the AMAR approval and subject to engaging with a strategic partner and sufficient available capital.”
Check-Cap’s C-Screen System was approved to provide structural information on endoluminal surfaces of the colon. It can be used to screen for colonic suspicious finding in adults who have an average risk of developing colorectal cancer and are not candidates for colonoscopies or decline colonoscopies.
The approval is valid until Feb. 28, 2019.
